[Research advances in immunotherapy for gastric cancer with specific molecular subtypes].

Gastric cancer is one of the most common malignant tumors. Immunotherapy has played a significant role in the neoadjuvant, conversion, and postoperative adjuvant treatment of gastric cancer. In recent years, immunotherapies such as immune checkpoint inhibitors, adoptive cell therapy, and antitumor vaccines have profoundly transformed the therapeutic landscape of gastric cancer. This review explores recent research progress in immunotherapy for gastric cancer with specific molecular subtypes, including HER2-positive, Claudin18.2-positive, dMMR/MSI-H, Epstein-Barr virus (EBV)-positive, and alpha-fetoprotein (AFP)-positive subtypes. The aim is to provide insights for developing personalized and precise treatment strategies for gastric cancer patients with different molecular subtypes and clinical stages.